据统计,我国矮小症患病率约3%,特发性矮小症(idiopathic short stature, ISS)占60%~80%,但接受治疗人数不足3万[1]。研究认为,ISS可能与营养、环境、遗传、精神及激素分泌紊乱有关[2]。重组人生长激素(rhGH)具有调节内分泌、刺激骨骼和...据统计,我国矮小症患病率约3%,特发性矮小症(idiopathic short stature, ISS)占60%~80%,但接受治疗人数不足3万[1]。研究认为,ISS可能与营养、环境、遗传、精神及激素分泌紊乱有关[2]。重组人生长激素(rhGH)具有调节内分泌、刺激骨骼和躯体生长作用,但临床实践显示,长疗程激素治疗易引发多种不良反应[3-4]。展开更多
【目的】探讨重组人生长激素（recombinant human growth hormone，rhGH）对青春期前特发性矮小症（Idiopathic short stature，ISS）儿童促身高增长的疗效。【方法】经胰岛素和左旋多巴药物联合激发试验测定生长激素（GH）确诊缺乏的IS...【目的】探讨重组人生长激素（recombinant human growth hormone，rhGH）对青春期前特发性矮小症（Idiopathic short stature，ISS）儿童促身高增长的疗效。【方法】经胰岛素和左旋多巴药物联合激发试验测定生长激素（GH）确诊缺乏的ISS儿童60例，每晚睡前皮下注射rhGH治疗0．15IU／（kg．d），疗程6个月，并对其疗效进行一年的观察。【结果】ISS患儿经生长激素治疗后，生长速率（．growt h velocity，GV）由治疗前测量的（3．61士0．42）cm／年提高到治疗后（7．69±3．31）cm／年，差异有显著性（P〈0．05）。身高由治疗前（134．12±14．14）cm提高到治疗后（141．20±13．88）cm，差异有显著性（P〈0．05）。治疗期间除少数肝功能轻度异常，有6例儿童在注射部位出现一过性红肿，双下肢轻度水肿和过敏性皮疹等，但未予处理后自行消失，另未发现其他明显副作用。【结论】皮下注射rhGH对治疗儿童ISS有增快生长速度作用，疗效肯定，是一种安全有效的方法，值得儿科临床推广应用。展开更多
Background: In children with severe rheumatic disease (RD), treatment with cor ticosteroids (CS) is frequently needed and growth retardation and osteopenia may develop. A beneficial effect of human growth hormone (hGH...Background: In children with severe rheumatic disease (RD), treatment with cor ticosteroids (CS) is frequently needed and growth retardation and osteopenia may develop. A beneficial effect of human growth hormone (hGH) has been reported bu t mostly in trials without a control group. Aims: To study the effect of hGH on growth, bone mineral density (BMD), and body composition, taking the disease act ivity and CS use into account. Methods: Randomised controlled trial on 17 prepub ertal RD patients with growth retardation and/or decreased BMD. The hGH group (n = 10) received treatment with hGH 4 IU/m2/day (～0.045 mg/kg/ day) during two y ears. The controls (n = 7) received no GH treatment. Results: During the two yea r study period the disease activity, and use of CS and metho- trexate (MTX) did not differ between the groups. There was a significant mean increase in height standard deviation score (HSDS) in the hGH group (0.42±0.16 SDS) and a non-significant decrease in the controls (-0.18±0.11 SDS). Change in BMD did not differ significantly between the groups, although the increase in BMD for lumbar spine within the hGH group was significant. Lean body mass impro ved significantly in the hGH group compared to controls (0.64±0.19 SDS versus -0.20±0.17 SDS), while the decrease in percentage fat was not significant. Con clusions: There was a significant effect of hGH on growth and lean body mass, bu t a longer duration of treatment might be necessary to evaluate the effect of hG H on BMD.展开更多
文摘据统计,我国矮小症患病率约3%,特发性矮小症(idiopathic short stature, ISS)占60%~80%,但接受治疗人数不足3万[1]。研究认为,ISS可能与营养、环境、遗传、精神及激素分泌紊乱有关[2]。重组人生长激素(rhGH)具有调节内分泌、刺激骨骼和躯体生长作用,但临床实践显示,长疗程激素治疗易引发多种不良反应[3-4]。
文摘【目的】探讨重组人生长激素（recombinant human growth hormone，rhGH）对青春期前特发性矮小症（Idiopathic short stature，ISS）儿童促身高增长的疗效。【方法】经胰岛素和左旋多巴药物联合激发试验测定生长激素（GH）确诊缺乏的ISS儿童60例，每晚睡前皮下注射rhGH治疗0．15IU／（kg．d），疗程6个月，并对其疗效进行一年的观察。【结果】ISS患儿经生长激素治疗后，生长速率（．growt h velocity，GV）由治疗前测量的（3．61士0．42）cm／年提高到治疗后（7．69±3．31）cm／年，差异有显著性（P〈0．05）。身高由治疗前（134．12±14．14）cm提高到治疗后（141．20±13．88）cm，差异有显著性（P〈0．05）。治疗期间除少数肝功能轻度异常，有6例儿童在注射部位出现一过性红肿，双下肢轻度水肿和过敏性皮疹等，但未予处理后自行消失，另未发现其他明显副作用。【结论】皮下注射rhGH对治疗儿童ISS有增快生长速度作用，疗效肯定，是一种安全有效的方法，值得儿科临床推广应用。
文摘Background: In children with severe rheumatic disease (RD), treatment with cor ticosteroids (CS) is frequently needed and growth retardation and osteopenia may develop. A beneficial effect of human growth hormone (hGH) has been reported bu t mostly in trials without a control group. Aims: To study the effect of hGH on growth, bone mineral density (BMD), and body composition, taking the disease act ivity and CS use into account. Methods: Randomised controlled trial on 17 prepub ertal RD patients with growth retardation and/or decreased BMD. The hGH group (n = 10) received treatment with hGH 4 IU/m2/day (～0.045 mg/kg/ day) during two y ears. The controls (n = 7) received no GH treatment. Results: During the two yea r study period the disease activity, and use of CS and metho- trexate (MTX) did not differ between the groups. There was a significant mean increase in height standard deviation score (HSDS) in the hGH group (0.42±0.16 SDS) and a non-significant decrease in the controls (-0.18±0.11 SDS). Change in BMD did not differ significantly between the groups, although the increase in BMD for lumbar spine within the hGH group was significant. Lean body mass impro ved significantly in the hGH group compared to controls (0.64±0.19 SDS versus -0.20±0.17 SDS), while the decrease in percentage fat was not significant. Con clusions: There was a significant effect of hGH on growth and lean body mass, bu t a longer duration of treatment might be necessary to evaluate the effect of hG H on BMD.
